“Embrace your weaknesses, only when you truly accept them can you begin to get better”
Dr. Negretti received a B.S. in Chemistry from the University of Puerto Rico-Río Piedras in 2008 and a Ph.D. in Medicinal Chemistry in 2014 from the University of Michigan-Ann Arbor. Her thesis research at Michigan, under the direction of Pro.f John Montgomery, focused on developing a bacterial P450 enzyme as a biocatalyst for C-H functionalization. While at the University of Michigan, Solymar was part of the NIH’s CBI training program. After her PhD, Solymar joined the Laboratory of Prof. Huw Davies at Emory University as postdoctoral research fellow . Her research at Emory focused on the development of novel dirhodium catalysts and their applications in organic synthesis. After her postdoctoral studies, Solymar started her industrial career as a medicinal chemist at ENANTA Pharmaceuticals, Inc. The research team she is part of focuses on the development of small-molecule therapeutics to treat Respiratory syncytial (sin-SISH-uhl) virus, or RSV. She employs her chemistry and biology knowledge to design and sythesize molecules to target the virus.